General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Opdivo-Yervoy (nivolumab-ipilimumab)
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
In neoadjuvant setting for resectable stage III melanoma.
Last updated February 21, 2025
Opdivo-Yervoy (nivolumab-ipilimumab)
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
In combination, for the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma when patients progress during or within 6 months of adjuvant PD-1 therapy.
Last updated August 1, 2025
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
As monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors
Last updated February 20, 2025
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
As monotherapy for the adjuvant treatment of adult patients with Stage IB (T2a 4 cm), II, or IIIA NSCLC, and with PD-L1 tumor proportion score (TPS) less than 50% who have undergone complete resection and platinum-based chemotherapy.
Last updated February 20, 2025
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
COVID-19 in hospitalized patients
Last updated February 18, 2025
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
COVID-19 in non-hospitalized patients
Last updated February 18, 2025
Status:
Concluded with an LOI
Manufacturer:
UCB Canada Inc.
Indication:
Psoriatic Arthritis
Last updated February 15, 2025
Status:
Concluded with an LOI
Manufacturer:
UCB Canada Inc.
Indication:
Ankylosing spondylitis
Last updated February 15, 2025
Adcetris (brentuximab vedotin)
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Hodgkin's Lymphoma
Last updated February 12, 2025
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Breast cancer, locally advanced or metastatic (HR-positive, HER2-negative)
Last updated February 12, 2025